PHARMACEUTICAL 2023

Royalty Pharma plc
Rank 204 of 471



RealRate

PHARMACEUTICAL 2023

Royalty Pharma plc
Rank 204 of 471

ROYALTY PHARMA

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 160% points.The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 284%, being 39% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	2,554,908
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,166,783
Liabilities, Non-Current	6,121,310
Other Assets	14,258,558
Other Compr. Net Income	-204,850
Other Expenses	1,525,741
Other Liabilities	0
Other Net Income	-77,001
Other Revenues	2,237,215
Property and Equipment	0
Research and Development	177,106
Selling, General and Administrative Expense	227,303

Output Variable	Value in 1000 USD
Assets	16,813,466
Liabilities	7,288,093
Expenses	1,930,150
Revenues	2,237,215
Stockholders Equity	9,525,373
Net Income	230,064
Comprehensive Net Income	127,639
BaseVar	14,275,388
ECR before LimitedLiability	173%
Economic Capital Ratio	284%